Torna al Registre Simple

 

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents

dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCasartelli, Chiara
dc.contributor.authorTommasi, Chiara
dc.contributor.authorLazzarin, Alessandro
dc.contributor.authorCorianò, Matilde
dc.contributor.authorTornali, C.
dc.contributor.authorSerra, Olga
dc.contributor.authorGutiérrez-Enríquez, Sara
dc.contributor.authorLlop-Guevara, Alba
dc.contributor.authorSerra, Violeta
dc.date.accessioned2024-07-10T12:16:38Z
dc.date.available2024-07-10T12:16:38Z
dc.date.issued2024-07-05
dc.identifier.citationCasartelli C, Tommasi C, Lazzarin A, Corianò M, Tornali C, Serra O, et al. Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents. ESMO Open. 2024 Jul 5;9(7):103629.
dc.identifier.issn2059-7029
dc.identifier.urihttps://hdl.handle.net/11351/11690
dc.descriptionFunció genètica; ADN
dc.description.sponsorshipThis work was supported by European Society for Medical Oncology to BP (no grant number) and ERA-NET Cofund [ERAPERMED 2019–215 to VS].
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesESMO Open;9(7)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCàncer - Aspectes genètics
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subjectADN - Dany
dc.subjectCromosomes humans - Anomalies - Diagnòstic
dc.subject.meshGenetic Testing
dc.subject.meshDNA Damage
dc.subject.meshNeoplasms
dc.subject.meshAntineoplastic Agents
dc.titleFunctional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.esmoop.2024.103629
dc.subject.decspruebas genéticas
dc.subject.decsdaño del ADN
dc.subject.decsneoplasias
dc.subject.decsantineoplásicos
dc.relation.publishversionhttps://doi.org/10.1016/j.esmoop.2024.103629
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Casartelli C, Tommasi C, Lazzarin A, Corianò M, Serra O] Department of Medicine and Surgery, University of Parma, Parma, Italy. Medical Oncology Unit, University Hospital of Parma, Parma, Italy. Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy. [Tornali C] Department of Medicine and Surgery, University of Parma, Parma, Italy. [Gutiérrez-Enríquez S] Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Llop-Guevara A, Serra V] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid38970842
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01303
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F01200
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Portada del document
Name:
functional_hrd_rad51_identifie ...
Grandària:
419.2Kb
Format:
PDF
Description:
Functional HRD by RAD51 identifies ...
Visualitza

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple